Navigation Links
Advanced Viral Announces Phase IIb Wound Healing Trial for AVR123
Date:10/28/2008

Receives $249,500 in Additional Financing

YONKERS, N.Y., Oct. 28 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR), announced today that it has commenced a Phase IIb efficacy study for AVR123 in wound healing.

The Phase IIb trial is being conducted at the Friedrich Alexander University Hospital in Erlangen Germany, led by Eckhart Kampgen, M.D., Associate Professor for Strategies of Cellular Immunotherapy at the Department of Dermatology. Dr. Kampgen is leading the Immunomonitoring, RNA and Melanoma Division at the hospital. He has over 80 peer-reviewed publications and has participated as Principal Investigator or Sub-Investigator in more than 20 Phase I, II and III clinical studies since 1995.

The primary objective of this study is to evaluate the effect of AVR123, applied topically, on the rate and quality of healing of wounds. According to the protocol, patients enrolled in the study will include individuals with a variety of wounds and dermatologic conditions.

AVR123 is a topical formulation of ARV118 which is currently being investigated for the systemic treatment of cancer related clinical cachexia. This compound has well-documented anti-inflammatory and wound healing activities. Results of a Phase I, open label, dose-escalating study indicated that topical AVR123 is well-tolerated, showing no dose-limiting toxicities. Initial observations of accelerated wound healing in a pig study at the University of Miami suggest that AVR123 may represent an important advance in the management of wounds.

Stephen Elliston, President and Chief Executive Officer of Advanced Viral, stated, "This trial has been designed to provide further evidence to substantiate encouraging preliminary results seen in the initial phase of the study, which was not completed due to the death of the study's Principal Investigator. We are highly fortunate to have Dr. Kampgen, a prestigious leader in the dermatological field
'/>"/>

SOURCE Advanced Viral Research Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015  Therapath Neuropathology ( www.Therapath.com ), a ... VA and Military Medical centers both domestically and ... and Sweat Gland Nerve Fiber Density (SGNFD) for ... ). Demonstration of a reduction ... punch skin biopsy is a highly sensitive and ...
(Date:7/29/2015)... SLOUGH, England , July 29, 2015  Indivior ... Application (NDA) for naloxone nasal spray was accepted and ... Administration (FDA) for the treatment of opioid overdose. This ... contains naloxone specially formulated for optimal absorption into the ... to require minimal training so individuals may be better ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company, is pleased to announce that ... injector (RCI-02) have been locked.  Prototypes for industrial ... prepare for an application for CE mark clearance ... in 2016. (Photo: ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Finding gooey ... morning is quite normal. Although there are a considerable number of terms in popular ... that this post-sleep material is a mixture of mucus, blood cells, skin cells and ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4
... , BALTIMORE, Sept. 9 ... company engaged in the development of advanced preclinical platforms and tumor ... at Rodman & Renshaw,s Eleventh Annual Healthcare Conference taking place September ... company,s Chairman of the Board, Dr. David Sidransky, will present on ...
... September 9 Biovista Inc.,today announced that BVA-201, its ... in the MOG-induced Experimental Allergic,Encephalomyelitis (EAE) murine model of ... MS and is aimed at neuroprotection. It was shown ... effects in this well,established model of MS. , ...
... , ISELIN, N.J., Sept. 9 ... company engaged in the development and commercialization of anti-adhesion ... barrier film for the reduction of adhesions following cardiac ... Health for use in all patients who undergo open-heart ...
Cached Biology Technology:Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference 2Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference 3Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis 2SyntheMed Receives Brazilian Regulatory Approval for REPEL-CV(TM) 2
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... water quality is good, the sport fish populations are sufficient, ... of birds. This positive trend is documented in a new ... the natural resources of Lake Mead and Lake Mohave, and ... Mead NRA. "While the Lake Mead ecosystem is generally ...
... biochemical structure in Burckhard Seelig,s lab at the University ... billions of years ago, when life on earth began ... new and improved products, from detergents to foods and ... directed evolution in the laboratory. Working with colleague Gianluigi ...
... different grape varietals can favorably balance the flavor characteristics ... of advanced biofuels might use a similar strategy, blending ... the transportation fuel they produce. A collaborative study ... Joint BioEnergy Institute (JBEI), a bioenergy research center led ...
Cached Biology News:Lake Mead aquatic-science research documents substantial improvements in ecosystem 2Lake Mead aquatic-science research documents substantial improvements in ecosystem 3U. of Minn. researchers unveil first artificial enzyme created by evolution in a test tube 2Biofuels blend right in 2Biofuels blend right in 3
...
p27 rabbit polyclonal antibody...
... Proliferation Marker, prediluted Ki67 antigen is ... expressed by proliferating cells in all phases ... G2 and M phase). It is absent ... useful in establishing the cell growing fraction ...
UBC13 Antibody...
Biology Products: